# T-cell Based Immunotherapy for Head and Neck Cancer

> **NCT00937300** · PHASE1 · WITHDRAWN · sponsor: **Inge Marie Svane**

## Conditions studied

- Squamous Cell Carcinoma
- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2

## Key facts

- **NCT ID:** NCT00937300
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The patients eligible for this trial do not exist anymore due to change in procedures.
- **Last updated:** 2011-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937300, "T-cell Based Immunotherapy for Head and Neck Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00937300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*